Figure 3: (a) 20-nail dystrophy before starting Itolizumab in Case 1; (b) Persistence of 20-nail dystrophy after completion of Itolizumab infusions; (c)Persistence of flexural disease in Case 2 after completion of Itolizumab infusions
|
|
Close |
|
Figure 3: (a) 20-nail dystrophy before starting Itolizumab in Case 1; (b) Persistence of 20-nail dystrophy after completion of Itolizumab infusions; (c)Persistence of flexural disease in Case 2 after completion of Itolizumab infusions
|
|